Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

Elizabeth H. Phillips, S Devereux, J Radford, N Mir, T Adedayo, L Clifton-Hadley, R Johnson

Research output: Contribution to journal › Letter › peer-review

Research Beacons, Institutes and Platforms

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{0a88a693de594be79296fed477be46a2,

title = "Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.",

author = "Phillips, {Elizabeth H.} and S Devereux and J Radford and N Mir and T Adedayo and L Clifton-Hadley and R Johnson",

year = "2019",

month = feb,

day = "18",

doi = "10.1080/10428194.2019.1576870",

language = "English",

journal = "Leukemia & lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

AU - Phillips, Elizabeth H.

AU - Devereux, S

AU - Radford, J

AU - Mir, N

AU - Adedayo, T

AU - Clifton-Hadley, L

AU - Johnson, R

PY - 2019/2/18

Y1 - 2019/2/18

U2 - 10.1080/10428194.2019.1576870

DO - 10.1080/10428194.2019.1576870

M3 - Letter

C2 - 30773077

SN - 1042-8194

JO - Leukemia & lymphoma

JF - Leukemia & lymphoma

ER -